PT - JOURNAL ARTICLE AU - Ali Kabir AU - Ahmad Sofi-Mahmudi AU - Arman Karimi Behnagh AU - Vahid Eidkhani AU - Hamid Reza Baradaran AU - Payam Kabiri AU - Ali Akbar Haghdoost AU - Bita Mesgarpour TI - The Risk of Bias in Iranian Randomized Controlled Trials Included in Cochrane Reviews AID - 10.1101/2020.08.02.20166728 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.02.20166728 4099 - http://medrxiv.org/content/early/2020/08/04/2020.08.02.20166728.short 4100 - http://medrxiv.org/content/early/2020/08/04/2020.08.02.20166728.full AB - Background Randomised controlled trials (RCT) provide the highest level of evidence among interventional studies. However, RCTs may be susceptible to the risk of bias (RoB). Therefore, systematic reviews appraise the RoB in all included studies in a review by using evaluation tools. This study aimed to describe the main characteristics of RCTs conducted in Iran and included in Cochrane Reviews (CRs) by focusing on their RoB.Methods We searched “Iran” by selecting the “Search All Text” field and “Review” in the Cochrane Database of systematic Review within Ovid. We retrieved CRs that included Iranian controlled trials. We selected trials only if they had involved human subjects, described as a controlled clinical trial, included in CRs and therefore the review authors assessed their RoBs. The characteristics of trials have been extracted by looking at the table “Characteristics of included studies” in each CRs as well as the relevant papers. To addressing RoB, we collected the judgment of the review authors according to the table of RoB assessments in CRs.Results There were 1166 Iranian RCTs included in 571 CRs. From all these studies, 44.9% were at low RoB for random sequence generation, 20.8% for allocation concealment, 32.3% for blinding of participants/personnel, 36.5% for blinding of outcome assessors, 56.3% for incomplete outcome data, 41.3% selective reporting, and 53.8% for other bias.Conclusion RoB was mainly high or unclear in Iranian RCTs. Special attention must be paid to methodological quality of RCTs in Iran accordingly.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request.